114 related articles for article (PubMed ID: 10987428)
1. Synthesis of a water-soluble prodrug of entacapone.
Leppänen J; Huuskonen J; Savolainen J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Järvinen T
Bioorg Med Chem Lett; 2000 Sep; 10(17):1967-9. PubMed ID: 10987428
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö PT; Järvinen T
J Pharm Pharmacol; 2001 Nov; 53(11):1489-98. PubMed ID: 11732751
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility.
Mahfouz NM; Hassan MA
J Pharm Pharmacol; 2001 Jun; 53(6):841-8. PubMed ID: 11428660
[TBL] [Abstract][Full Text] [Related]
5. Absorption rate limit considerations for oral phosphate prodrugs.
Heimbach T; Oh DM; Li LY; Forsberg M; Savolainen J; Leppänen J; Matsunaga Y; Flynn G; Fleisher D
Pharm Res; 2003 Jun; 20(6):848-56. PubMed ID: 12817887
[TBL] [Abstract][Full Text] [Related]
6. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution.
Orama M; Tilus P; Taskinen J; Lotta T
J Pharm Sci; 1997 Jul; 86(7):827-31. PubMed ID: 9232524
[TBL] [Abstract][Full Text] [Related]
7. Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide.
Juntunen J; Huuskonen J; Laine K; Niemi R; Taipale H; Nevalainen T; Pate DW; Järvinen T
Eur J Pharm Sci; 2003 May; 19(1):37-43. PubMed ID: 12729860
[TBL] [Abstract][Full Text] [Related]
8. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Alqahtani S; Kaddoumi A
Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of water-soluble polymeric prodrugs possessing 4-methylcatechol derivatives by mechanochemical solid-state copolymerization and nature of drug release.
Kondo S; Sasai Y; Kuzuya M; Furukawa S
Chem Pharm Bull (Tokyo); 2002 Nov; 50(11):1434-8. PubMed ID: 12419905
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.
Hasabelnaby S; Goudah A; Agarwal HK; abd Alla MS; Tjarks W
Eur J Med Chem; 2012 Sep; 55():325-34. PubMed ID: 22889558
[TBL] [Abstract][Full Text] [Related]
11. Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation.
Tammara VK; Narurkar MM; Crider AM; Khan MA
J Pharm Sci; 1994 May; 83(5):644-8. PubMed ID: 8071813
[TBL] [Abstract][Full Text] [Related]
12. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
Forsberg MM; Huotari M; Savolainen J; Männistö PT
Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
[TBL] [Abstract][Full Text] [Related]
13. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.
Nissinen E; Kaheinen P; Penttilä KE; Kaivola J; Lindén IB
Eur J Pharmacol; 1997 Dec; 340(2-3):287-94. PubMed ID: 9537825
[TBL] [Abstract][Full Text] [Related]
14. Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media.
Kumar V; Bharate SS; Vishwakarma RA
Eur J Pharm Sci; 2016 Sep; 92():203-11. PubMed ID: 27422078
[TBL] [Abstract][Full Text] [Related]
15. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
Nissinen E; Lindén IB; Schultz E; Pohto P
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
18. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.
Hamada Y; Ohtake J; Sohma Y; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2002 Dec; 10(12):4155-67. PubMed ID: 12413869
[TBL] [Abstract][Full Text] [Related]
19. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
